Assignee
MEDAREX INC
US87 patents
Top patents by PatentIndex Score
US9102725B2Aug 11, 2015
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
MEDAREX INC120 citations99
US8383796B2Feb 26, 2013
Nucleic acids encoding monoclonal antibodies to programmed death ligand 1 (PD-L1)
MEDAREX INC355 citations99
US8017114B2Sep 13, 2011
Human CTLA-4 antibodies and their uses
MEDAREX INC199 citations99
US8008449B2Aug 30, 2011
Human monoclonal antibodies to programmed death 1 (PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
MEDAREX INC2,199 citations99
US7943743B2May 17, 2011
Human monoclonal antibodies to programmed death ligand 1 (PD-L1)
MEDAREX INC1,485 citations99
US7605238B2Oct 20, 2009
Human CTLA-4 antibodies and their uses
MEDAREX INC353 citations99
US7501552B2Mar 10, 2009
Transgenic non-human animals for producing chimeric antibodies
MEDAREX INC182 citations99
US6984720B1Jan 10, 2006
Human CTLA-4 antibodies
MEDAREX INC897 citations99
US6303755B1Oct 16, 2001
Therapeutic multispecific compounds comprised of anti-FCA receptor antibodies
MEDAREX INC116 citations99
US5922845AJul 13, 1999
Therapeutic multispecific compounds comprised of anti-Fcα receptor antibodies
MEDAREX INC448 citations99
US7910798B2Mar 22, 2011
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
MEDAREX INC130 citations98
US7662381B2Feb 16, 2010
Interferon alpha receptor 1 antibodies and their uses
MEDAREX INC47 citations98
US7517903B2Apr 14, 2009
Cytotoxic compounds and conjugates
MEDAREX INC161 citations98
US7507420B2Mar 24, 2009
Peptidyl prodrugs and linkers and stabilizers useful therefor
MEDAREX INC148 citations98
US7498302B2Mar 3, 2009
Disulfide prodrugs and linkers and stabilizers useful therefor
MEDAREX INC123 citations98
US7129261B2Oct 31, 2006
Cytotoxic agents
MEDAREX INC282 citations98
US7087600B2Aug 8, 2006
Peptidyl prodrugs and linkers and stabilizers useful therefor
MEDAREX INC259 citations98
US6989452B2Jan 24, 2006
Disulfide prodrugs and linkers and stabilizers useful therefor
MEDAREX INC284 citations98
US6682928B2Jan 27, 2004
Cells expressing anti-Fc receptor binding components
MEDAREX INC89 citations98
US6410690B1Jun 25, 2002
Therapeutic compounds comprised of anti-Fc receptor antibodies
MEDAREX INC91 citations98
US6365161B1Apr 2, 2002
Therapeutic compounds comprised of anti-FC receptor binding agents
MEDAREX INC113 citations98
US6270765B1Aug 7, 2001
Therapeutic compounds comprised of anti-Fc receptor antibodies
MEDAREX INC215 citations98
US5837243ANov 17, 1998
Therapeutic compounds comprised of anti-Fc receptor antibodies
MEDAREX INC545 citations98
US7387776B2Jun 17, 2008
Human monoclonal antibodies against CD30
MEDAREX INC70 citations97
US6063116AMay 16, 2000
Modulation of cell proliferation and wound healing
MEDAREX INC259 citations97
US7875278B2Jan 25, 2011
Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues
MEDAREX INC56 citations96
US7691962B2Apr 6, 2010
Chemical linkers and conjugates thereof
MEDAREX INC200 citations96
US7456264B2Nov 25, 2008
Human monoclonal antibodies against Bacillus anthracis protective antigen
MEDAREX INC88 citations96
US7214663B2May 8, 2007
Tripeptide prodrug compounds
MEDAREX INC52 citations96
US7135287B1Nov 14, 2006
Human antibodies
MEDAREX INC62 citations96
US7115573B2Oct 3, 2006
Prodrug compounds with an isoleucine
MEDAREX INC61 citations96
US5833985ANov 10, 1998
Bispecific molecules for use in inducing antibody dependent effector cell-mediated cytotoxicity
MEDAREX INC163 citations96
US8034959B2Oct 11, 2011
Methods of treating cancer with an antibody-drug conjugate
MEDAREX INC37 citations95
US7452535B2Nov 18, 2008
Methods of treatment using CTLA-4 antibodies
MEDAREX INC70 citations95
US6962981B1Nov 8, 2005
Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen
MEDAREX INC52 citations95
US6897034B2May 24, 2005
CD10-activated prodrug compounds
MEDAREX INC52 citations95
US7465446B2Dec 16, 2008
Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease
MEDAREX INC52 citations94
US6248332B1Jun 19, 2001
Targeted immunostimulation with bispecific reagents
MEDAREX INC41 citations94
US6071517AJun 6, 2000
Bispecific heteroantibodies with dual effector functions
MEDAREX INC85 citations94
US7847105B2Dec 7, 2010
Methods and compounds for preparing CC-1065 analogs
MEDAREX INC33 citations93
US7368098B2May 6, 2008
Use of biomolecular targets in the treatment and visualization of tumors
MEDAREX INC43 citations93
US8802632B2Aug 12, 2014
Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
MEDAREX INC12 citations92
US8383118B2Feb 26, 2013
Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1
MEDAREX INC24 citations92
US7977465B2Jul 12, 2011
Peptidyl prodrugs and linkers and stabilizers useful therefor
MEDAREX INC14 citations92
US7968586B2Jun 28, 2011
Cytotoxic compounds and conjugates
MEDAREX INC39 citations92
US7741449B2Jun 22, 2010
Anti-interferon alpha antibodies
MEDAREX INC19 citations92
US7714016B2May 11, 2010
Cytotoxic compounds and conjugates with cleavable substrates
MEDAREX INC45 citations92
US7476513B2Jan 13, 2009
Monoclonal antibody specific for the extracellular domain of prostate specific membrane antigen
MEDAREX INC29 citations92
US7329507B2Feb 12, 2008
Prodrug compounds with isoleucine
MEDAREX INC27 citations92
US7304032B2Dec 4, 2007
CD-10 activated prodrug compounds
MEDAREX INC31 citations92
Showing the top 50 of 87 patents by PatentIndex Score.